1. Measurability of Tumors at Baseline
2. Non-measurable Lesions
3. Assessment of Lymph Nodes
4. Bone Lesion Measurability
5. Cystic Lesions
6. Prior Local Treatment of Lesions
7. Presence of Measurable Disease at Baseline
8. Baseline Documentation of Target Lesions
9. Documentation of Non-target Lesions
10. Definition of Complete Response (CR)
11. Definition of Progressive Disease (LR)
12. Definition of Unequivocal Progression
13. Too Small to Measure
14. Lesions that Split or Coalesce
15. New Lesions
16. PET
17. Missing Assessments and Inevaluable Designation
18. Overall Response Table, Subjects With Measurable Disease
19. Overall Response Table, Subjects Without Measurable Disease
20. Best Overall Response
21. Confirmation Measurement / Duration of Response
22. Lesion Reappearance
23. Protocol Design Considerations: Study Endpoints
24. Protocol Design Considerations: Imaging Modalities

Blue squares indicate changes from RECIST 1.0 to RECIST 1.1